Normal cells and tumor cell lines used in this study
| Cells . | HLA-A2expressiona . | p53 statusb . | p53264–272 presentation . |
|---|---|---|---|
| Tumors | |||
| HR | + | mm/codon 306c | ND |
| MCF-7 | + | wtd | + |
| SCC-4 | + | mm/codon 155e | − |
| SCC-9 | + | Deletion 275–285e | + |
| OSC-19 | + | mm/codon 225 | ND |
| PCI-4B | − | wt | − |
| PCI-13 | + | mm/codon 286 | + |
| PCI-30 | + | wt | ND |
| Normal cells | |||
| PHA-lymphoblasts | + | wt | − |
| Cells . | HLA-A2expressiona . | p53 statusb . | p53264–272 presentation . |
|---|---|---|---|
| Tumors | |||
| HR | + | mm/codon 306c | ND |
| MCF-7 | + | wtd | + |
| SCC-4 | + | mm/codon 155e | − |
| SCC-9 | + | Deletion 275–285e | + |
| OSC-19 | + | mm/codon 225 | ND |
| PCI-4B | − | wt | − |
| PCI-13 | + | mm/codon 286 | + |
| PCI-30 | + | wt | ND |
| Normal cells | |||
| PHA-lymphoblasts | + | wt | − |
HLA-A2 expression was determined serologically.
Based on sequence analysis of reverse transcription-PCR products corresponding to p53 exons 5–8, as detailed in “Materials and Methods” or in the cited references.
mm, missense mutation; wt, wild-type sequence; ND, not determined.
Based on the analysis detailed in Ref. 20.
Based on the analysis detailed in Ref. 19.